Cancer Research and Treatment

Original Articles

Safety and Effectiveness of Eribulin in Patients with Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes in Real-World Clinical Practice: A 6-Year Post-Marketing Surveillance Study in South Korea: Yee Soo Chae, Kyung A Kwon, Moon Hee Lee, Mi Sun Ahn, Kyung-Hun Lee, Su-Jin Koh, Joohyuk Sohn, Keon Uk Park, Min Young Kim, Youngji Pyo, Bo Young Kim, Kyung Hae Jung; Received November 27, 2024 Accepted April 26, 2025 Published online April 28, 2025; DOI: https://doi.org/10.4143/crt.2024.1142 [Accepted]

Abstract PDF: Purpose
This 6-year post-marketing surveillance (PMS) study was conducted in South Korea to evaluate the real-world safety and effectiveness of eribulin in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
Materials and Methods
During the study period (17 August 2012 to 16 August 2018), case-report files (CRFs) of patients receiving eribulin were collected. The main study endpoint was to assess the safety of eribulin. Evaluation of the effectiveness of eribulin was an exploratory endpoint. Patients were followed for 1 year after eribulin initiation.
Results
CRFs were collected from 64 investigators at 64 sites for 1079 patients. The safety analysis set (SAS) included 1,001 eribulin recipients; effectiveness was assessed in 244 patients. In the SAS, patients were predominantly female (99.6%), with a median age of 53.0 years, and diagnosed with metastatic breast cancer (92.0%). Eribulin was administered as a median 4th line chemotherapy. A total of 2,124 TEAEs were reported in 661 patients (66.0%). Neutropenia was the most common TEAE (32.5% of patients), occurring at a median of 9–11 days from initial eribulin administration. Overall response and disease control rates were 31.7% and 95.6%, respectively, and the median duration of eribulin use (time to treatment failure) was 3.0 months.
Conclusion
This large real-world PMS analysis in patients with advanced or metastatic breast cancer demonstrated the effectiveness of eribulin and found no new safety concerns relative to safety information from prior clinical and real-world studies, and approvals in South Korea and other countries.

230 View
16 Download

Breast cancer

Eflapegrastim versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies: Yong Wha Moon, Seung Ki Kim, Keun Seok Lee, Moon Hee Lee, Yeon Hee Park, Kyong Hwa Park, Gun Min Kim, Seungtaek Lim, Seung Ah Lee, Jae Duk Choi, Eunhye Baek, Hyesun Han, Seungjae Baek, Seock-Ah Im; Cancer Res Treat. 2023;55(3):766-777. Published online January 19, 2023; DOI: https://doi.org/10.4143/crt.2022.987

Abstract PDF Supplementary Material PubReader ePub

Purpose
We investigated the consistent efficacy and safety of eflapegrastim, a novel long-acting granulocyte-colony stimulating factor (G-CSF), in Koreans and Asians compared with the pooled population of two global phase 3 trials.
Materials and Methods
Two phase 3 trials (ADVANCE and RECOVER) evaluated the efficacy and safety of fixed-dose eflapegrastim (13.2 mg/0.6 mL [3.6 mg G-CSF equivalent]) compared to pegfilgrastim (6 mg based on G-CSF) in breast cancer patients who received neoadjuvant or adjuvant docetaxel/cyclophosphamide. The primary objective was to demonstrate non-inferiority of eflapegrastim compared to pegfilgrastim in mean duration of severe neutropenia (DSN) in cycle 1, in Korean and Asian subpopulations.
Results
Among a total of 643 patients randomized to eflapegrastim (n=314) or pegfilgrastim (n=329), 54 Asians (29 to eflapegrastim and 25 to pegfilgrastim) including 28 Koreans (14 to both eflapegrastim and pegfilgrastim) were enrolled. The primary endpoint, DSN in cycle 1 in the eflapegrastim arm was non-inferior to the pegfilgrastim arm in Koreans and Asians. The DSN difference between the eflapegrastim and pegfilgrastim arms was consistent across populations: –0.120 days (95% confidence interval [CI], –0.227 to –0.016), –0.288 (95% CI, –0.714 to 0.143), and –0.267 (95% CI, –0.697 to 0.110) for pooled population, Koreans and Asians, respectively. There were few treatment-related adverse events that caused discontinuation of eflapegrastim (1.9%) or pegfilgrastim (1.5%) in total and no notable trends or differences across patient populations.
Conclusion
This study may suggest that eflapegrastim showed non-inferior efficacy and similar safety compared to pegfilgrastim in Koreans and Asians, consistently with those of pooled population.

Citations

Citations to this article as recorded by

Comparison of Prophylactic Efficacy of Eflapegrastim and Pegteograstim for Chemotherapy-induced Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX/mFOLFIRINOX
Eui Seon Lee, Min Jung Geum, Jong Hee Ko, Jae Song Kim, Eun Sun Son, Yun Mi Yu
Journal of Korean Society of Health-System Pharmacists.2024; 41(3): 253. CrossRef

5,125 View
277 Download
1 Crossref

A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03): Dae-Won Lee, Bhumsuk Keam, Keun Seok Lee, Jin-Hee Ahn, Joohyuk Sohn, Jin Seok Ahn, Moon Hee Lee, Jee Hyun Kim, Kyung Eun Lee, Hyo Jung Kim, Si-Young Kim, Yeon Hee Park, Chan-Young Ock, Kyung-Hun Lee, Sae-Won Han, Sung-Bae Kim, Young Hyuck Im, Hyun Cheol Chung, Do-Youn Oh, Seock-Ah Im; Cancer Res Treat. 2023;55(2):523-530. Published online November 8, 2022; DOI: https://doi.org/10.4143/crt.2022.1360

Abstract PDF PubReader ePub

Purpose
This single-arm phase II trial investigate the efficacy and safety of S-1 plus oxaliplatin (SOX) in patients with metastatic breast cancer.
Materials and Methods
Patients with metastatic breast cancer previously treated with anthracyclines and taxanes were enrolled. Patients received S-1 (40-60 mg depending on patient’s body surface area, twice a day, day 1-14) and oxaliplatin (130 mg/m2, day 1) in 3 weeks cycle until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumor 1.1. Secondary endpoints included time-to-progression (TTP), duration-of-response (DoR), overall survival (OS), and adverse events.
Results
A total of 87 patients were enrolled from 11 institutions in Korea. Hormone receptor was positive in 54 (62.1%) patients and six (6.9%) had human epidermal growth factor receptor 2–positive disease. Forty-eight patients (85.1%) had visceral metastasis and 74 (55.2%) had more than three sites of metastases. The ORR of SOX regimen was 38.5% (95% confidence interval [CI], 26.9 to 50.0) with a median TTP of 6.0 months (95% CI, 5.1 to 6.9). Median DoR and OS were 10.3 months (95% CI, 5.5 to 15.1) and 19.4 (95% CI, not estimated) months, respectively. Grade 3 or 4 neutropenia was reported in 28 patients (32.1%) and thrombocytopenia was observed in 23 patients (26.6%).
Conclusion
This phase II study showed that SOX regimen is a reasonable option in metastatic breast cancer previously treated with anthracyclines and taxanes.

Citations

Citations to this article as recorded by

Unraveling the immune landscape and therapeutic biomarker PMEPA1 for oxaliplatin resistance in colorectal cancer: A comprehensive approach
Zhengguang Zhang, Tianming Lu, Zhe Zhang, Zixian Liu, Ruoning Qian, Ruogu Qi, Fuqiong Zhou, Min Li
Biochemical Pharmacology.2024; 222: 116117. CrossRef
Efficacy and safety of utidelone plus capecitabine in advanced first-line therapy for metastatic breast cancer: A multicenter real-world study
Pingping Bi, Xi Wang, Rui Liu, Xiuqin Li, Shanrong Wei, Jiawen Zhao, Xin Tan, Fan Zhang, Qing Mao, Ying Zhang, Baoyan Tang, Xueqiong Xun, Rong Guo, Kai Zheng, Shaoqiang Zhou, Shicong Tang
Surgery Open Science.2023; 16: 171. CrossRef

5,055 View
173 Download
2 Web of Science
2 Crossref

S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial: Choong-kun Lee, Minkyu Jung, Hyo Song Kim, Inkyung Jung, Dong Bok Shin, Seok Yun Kang, Dae Young Zang, Ki Hyang Kim, Moon Hee Lee, Bong-Seog Kim, Kyung Hee Lee, Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh, Hyun Cheol Chung, Sun Young Rha; Cancer Res Treat. 2019;51(1):1-11. Published online February 5, 2018; DOI: https://doi.org/10.4143/crt.2018.028

Abstract PDF Supplementary Material PubReader ePub

Purpose
We conducted a randomized, multicenter, phase III trial to compare S-1 plus docetaxel (DS) with S-1 plus cisplatin (SP) as adjuvant chemotherapy for stage III gastric cancer patients.
Materials and Methods
Stage III gastric cancer patients who had received curative gastrectomy with D2 lymphadenectomy were randomized into equal groups to receive adjuvant chemotherapy of eight cycles of DS (S-1 70 mg/m² /day on days 1-14 plus docetaxel 35 mg/m² on days 1 and 8) every 3 weeks or SP (S-1 70 mg/m² /day on days 1-14 plus cisplatin 60 mg/m² on day 1) every 3 weeks. The primary endpoint was 3-year disease-free survival (DFS) rate.
Results
Between November 2010 and July 2013, 153 patients (75 patients to DS and 78 patients to SP) were enrolled from 8 institutions in Korea. After the capecitabine plus oxaliplatin was approved based on the CLASSIC study, itwas decided to close the study early. With a median follow-up duration of 56.9 months, the 3-year DFS rate between two groups was not significantly different (49.14% in DS group vs. 52.5% in SP group). The most common grade 3-4 adverse event was neutropenia (42.7% in DS and 38.5% in SP, p=0.351). SP group had more grade 3-4 anemia (1.3% vs. 11.5%, p=0.037), whereas grade 3-4 hand-foot syndrome (4.1% vs. 0%, p=0.025) and mucositis (10.7% vs. 2.6%, p=0.001) were more common in DS group. Fifty-one patients (68%) in DS group and 52 (66.7%) in SP group finished planned treatment.
Conclusion
Our findings suggest that SP or DS is an effective and tolerable option for patients with curatively resected stage III gastric cancer.

Citations

Citations to this article as recorded by

Efficacy and safety of docetaxel plus S-1-based therapy in gastric cancer: a quantitative evidence synthesis of randomized controlled trials
Hui-Fen Lv, Li-Feng Qin, Rui-Zhi Ran, Xue-Ping Jiang, Fang-Yu Zhao, Bo Li
Frontiers in Pharmacology.2024;[Epub] CrossRef
A novel method of bedside hyperthermic intraperitoneal chemotherapy as adjuvant therapy for stage-III gastric cancer
Lili Liu, Li Sun, Ning Zhang, Cheng-gong Liao, Haichuan Su, Jie Min, Yang Song, Xue Yang, Xiaofeng Huang, Dongxu Chen, Yu Chen, Hong-wei Zhang, Helong Zhang
International Journal of Hyperthermia.2022; 39(1): 239. CrossRef
Comment on “post-discharge oral nutritional supplements with dietary advice in patients at nutritional risk after surgery for gastric cancer: A randomized clinical trial”
Qiang Hu, Yuanshui Sun
Clinical Nutrition.2021; 40(3): 1438. CrossRef
THE ROLE OF ADJUVANT CHEMOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED GASTRIC CANCER
A. A. Bobryshev, M. M. Davudov, M. N. Narimanov, S. B. Polycarpova, V. Y. Kirsanov, V. N. Blindar
Siberian journal of oncology.2021; 20(1): 133. CrossRef
Multidisciplinary treatment strategy for locally advanced gastric cancer: A systematic review
Kotaro Sugawara, Yoshikuni Kawaguchi, Yasuyuki Seto, Jean-Nicolas Vauthey
Surgical Oncology.2021; 38: 101599. CrossRef
Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis
Chih-Chieh Yen, Yan-Shen Shan, Ying-Jui Chao, Ting-Kai Liao, I-Shu Chen, Hsuan-Yi Huang, I-Ting Liu, Chia-Jui Yen
BMC Cancer.2021;[Epub] CrossRef
Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren’s Classification in Pan–Cancer Analysis Era?
Ina Valeria Zurlo, Michele Basso, Antonia Strippoli, Maria Alessandra Calegari, Armando Orlandi, Alessandra Cassano, Mariantonietta Di Salvatore, Giovanna Garufi, Emilio Bria, Giampaolo Tortora, Carlo Barone, Carmelo Pozzo
Cancers.2020; 12(7): 1749. CrossRef
A systematic review and network meta-analysis protocol of adjuvant chemotherapy regimens for resected gastric cancer
Long Ge, Liangying Hou, Qingxia Yang, Yiting Wu, Xiue Shi, Jiang Li, Kehu Yang
Medicine.2019; 98(7): e14478. CrossRef
Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis
Tom van den Ende, Emil ter Veer, Rosa M. A. Mali, Mark I. van Berge Henegouwen, Maarten C. C. M. Hulshof, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
Cancers.2019; 11(4): 530. CrossRef
COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis
Tom van den Ende, Frank A. Abe Nijenhuis, Héctor G. van den Boorn, Emil ter Veer, Maarten C. C. M. Hulshof, Suzanne S. Gisbertz, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
Frontiers in Oncology.2019;[Epub] CrossRef
Cutting-edge evidence of adjuvant treatments for gastric cancer
Dai Shimizu, Mitsuro Kanda, Yasuhiro Kodera, Junichi Sakamoto
Expert Review of Gastroenterology & Hepatology.2018; 12(11): 1109. CrossRef

13,400 View
592 Download
22 Web of Science
11 Crossref

Case Reports

A Case of Blastic Plasmacytoid Dendritic Cell Neoplasm Initially Mimicking Cutaneous Lupus Erythematosus: Hye Jung Chang, Myung Dong Lee, Hyeon Gyu Yi, Joo Han Lim, Moon Hee Lee, Jeong Hyun Shin, Suk Jin Choi, Yeonsook Moon, Chung Hyun Nahm, Chul Soo Kim; Cancer Res Treat. 2010;42(4):239-243. Published online December 31, 2010; DOI: https://doi.org/10.4143/crt.2010.42.4.239

Abstract PDF PubReader ePub

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease. The prognosis is poor in most cases with rapid progression despite administering chemotherapy. A 67-year-old man complained of skin rashes on his back and this spread to the trunk, face, arms and thighs, and he was initially diagnosed with cutaneous lupus erythematosus according to the skin biopsy. The skin rashes then became aggravated on a trial of low dose methylprednisolone for 3 months. Repeated skin biopsy revealed a diffuse infiltration of lymphoid cells with medium sized nuclei, positive for CD4 and CD56, negative for Epstein-Barr virus (EBV), indicating a diagnosis of BPDCN. Further workups confirmed stage IVA BPDCN involving the skin, multiple lymph nodes, the peripheral blood and the bone marrow. He was treated with six cycles of combination chemotherapy consisting of ifosphamide, methotrexate, etoposide, prednisolone and L-asparaginase, and he achieved a partial response. Herein we report on a rare case of BPDCN that was initially misinterpreted as cutaneous lupus erythematosus.

Citations

Citations to this article as recorded by

Blastic plasmacytoid dendritic cell neoplasm misdiagnosed and treated as acute febrile neutrophilic dermatosis
Yuqing Song, Yingying Dong, Lin Gong
Indian Journal of Dermatology, Venereology and Leprology.2025; 0: 1. CrossRef
Blastic Plasmacytoid Dendritic Cell Neoplasm, from a Dermatological Point of View
Cosimo Di Raimondo, Flavia Lozzi, Pier Paolo Di Domenico, Claudia Paganini, Elena Campione, Marco Galluzzo, Luca Bianchi
International Journal of Molecular Sciences.2024; 25(13): 7099. CrossRef
Chemotherapy Options for Blastic Plasmacytoid Dendritic Cell Neoplasm
Michael Haddadin, Justin Taylor
Hematology/Oncology Clinics of North America.2020; 34(3): 539. CrossRef
Dendritic Cell Leukemia: a Review
Nikolaos J. Tsagarakis, Georgios Paterakis
Current Oncology Reports.2020;[Epub] CrossRef
Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm: A Systematic Literature Review
Marie Jeong-Min Kim, Ahmed Nasr, Bilaal Kabir, Joseph de Nanassy, Ken Tang, Danielle Menzies-Toman, Donna Johnston, Dina El Demellawy
Journal of Pediatric Hematology/Oncology.2017; 39(7): 528. CrossRef
Simultaneous deletion of 3′ETV6 and 5′EWSR1 genes in blastic plasmacytoid dendritic cell neoplasm: case report and literature review
Zhenya Tang, Guilin Tang, Sa A. Wang, Xinyan Lu, Ken H. Young, Carlos E. Bueso-Ramos, Yesid Alvarado, L. Jeffrey Medeiros, Joseph D. Khoury
Molecular Cytogenetics.2016;[Epub] CrossRef
NK-Cell Lymphoblastic Leukemia/Lymphoma (Literature Review and Authors' Experience)
M.A. Frenkel', O.Yu. Baranova, Alina Sergeevna Antipova, N.A. Kupryshina, N.N. Tupitsyn
Clinical oncohematology.2016; 9(2): 208. CrossRef
Blastic plasmacytoid dendritic neoplasm (BPDN) or BPDN-like lesion presenting after influenza vaccination and resolving with topical high potency steroid
Jonathan Yao, Joanna Dong, James Strauchen, Rajendra Singh
JAAD Case Reports.2015; 1(4): 203. CrossRef
Lupus mimickers
Omar-Javier Calixto, Juan-Sebastian Franco, Juan-Manuel Anaya
Autoimmunity Reviews.2014; 13(8): 865. CrossRef
Diagnostic and Therapeutic Advances in Blastic Plasmacytoid Dendritic Cell Neoplasm: A Focus on Hematopoietic Cell Transplantation
Mohamed A. Kharfan-Dabaja, Hillard M. Lazarus, Taiga Nishihori, Rami A. Mahfouz, Mehdi Hamadani
Biology of Blood and Marrow Transplantation.2013; 19(7): 1006. CrossRef
Cutaneous blastic plasmacytoid dendritic cell neoplasm occurring after spontaneous remission of acute myeloid leukemia: a case report and review of literature
Wanzhuo Xie, Yanmin Zhao, Ling Cao, Weijia Huang, Yanli Wang, He Huang
Medical Oncology.2012; 29(4): 2417. CrossRef
Cutaneous lupus erythematosus: a great imitator
Ashok Kumar Khare
Expert Review of Dermatology.2011; 6(6): 555. CrossRef

12,485 View
81 Download
12 Crossref

Plasmablastic Lymphoma in the Anal Canal: Joo Han Lim, Moon Hee Lee, Man Jong Lee, Chul Soo Kim, Jin Soo Lee, Suk Jin Choi, Hyeon Gyu Yi; Cancer Res Treat. 2009;41(3):182-185. Published online September 28, 2009; DOI: https://doi.org/10.4143/crt.2009.41.3.182

Abstract PDF PubReader ePub

Plasmablastic lymphoma (PBL) of the oral cavity is an acquired immunodeficiency syndrome-related lymphoma. The immunophenotype of this disease is associated with poor expression of B-cell markers but a positive reactivity for plasma cell markers. PBL is highly aggressive and responds poorly to treatment. Although originally described in the oral cavity, this disease can occur in other body niches. Here, we describe a very rare case of PBL in the anal canal of a 40-year-old woman with human immunodeficiency virus infection. The malignant cells were positive for Epstein-Barr virus and human herpes virus 8.

Citations

Citations to this article as recorded by

Anal lymphoma: a tumor with insufficient attention
Xibo Liu, Hongliang Chen
Discover Oncology.2023;[Epub] CrossRef
A Case of Anal Malignant Lymphoma in which Excisional Biopsy was Useful for Confirming the Diagnosis
Shun AKIYAMA, Mitsuru YOKOTA, Akitaka MORIKAWA, Michio OKABE, Hirohisa KITAGAWA, Kazuyuki KAWAMOTO
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2023; 84(4): 620. CrossRef
Anorectal pathology in the HIV population: a guide for radiologists
Derek Vos, Margaret Wang, Sita Ramaiya, Elias G. Kikano, Sree H. Tirumani, Daniel A. Smith
Abdominal Radiology.2022; 47(5): 1762. CrossRef
Plasmablastic Lymphoma of the Small Intestine in an HIV- and EBV-negative Patient
Yuka Fukuo, Tomoyoshi Shibuya, Karin Ashizawa, Kentaro Ito, Michio Saeki, Hirofumi Fukushima, Masahito Takahashi, Kei Nomura, Koki Okahara, Keiichi Haga, Yoichi Akazawa, Osamu Nomura, Kanako Ogura, Hironao Okubo, Akihito Nagahara
Internal Medicine.2021; 60(18): 2947. CrossRef
Fistulizing Epstein-Barr virus-positive plasmablastic lymphoma in an HIV-positive man
J. Rangel, R. Novoa, C. Morrison, D. Frank, C. Kovarik
British Journal of Dermatology.2016; 174(2): 398. CrossRef
Linfoma plasmablástico anal. Reporte de dos casos
Cristina Grijalva-Santana, David San Marcos-Romero, Billy Jiménez-Bobadilla, Saulo Mendoza-Ramírez, Milly Diorey Reyes-Hansen, Carlos Cosme-Reyes
Cirujano General.2016; 38(2): 78. CrossRef
Plasmoblastic Lymphoma as Cause of Perianal Fistula
Firoozeh Isfahani, Surabhi Amar, Harikrishna Dave, Daniel Gridley
Journal of the International Association of Providers of AIDS Care (JIAPAC).2015; 14(1): 17. CrossRef
A Case of Oral Plasmablastic Lymphoma and Review of Current Trends in Oral Manifestations Associated With Human Immunodeficiency Virus Infection
Nicholas Medel, Aya Hamao-Sakamoto
Journal of Oral and Maxillofacial Surgery.2014; 72(9): 1729. CrossRef
Plasmablastic Lymphoma of the Anal Canal in an HIV-Infected Patient
Agnaldo José Lopes
American Journal of Case Reports.2014; 15: 543. CrossRef
Manifestations of gastrointestinal plasmablastic lymphoma: A case series with literature review
Lynette Luria
World Journal of Gastroenterology.2014; 20(33): 11894. CrossRef
A Case of Anal Malignant Lymphoma Coexistent with Adult T-cell Leukemia
Katsuhisa Ohashi, Akinori Sasaki, Yoshihiro Matsuo, Katsuhide Ohashi
Nippon Daicho Komonbyo Gakkai Zasshi.2013; 66(4): 269. CrossRef
Extraoral plasmablastic lymphoma with intravascular component and MYC translocation
Jennifer Chapman-Fredricks, Naomi Montague, Ikechukwu Akunyili, Offiong Ikpatt
Annals of Diagnostic Pathology.2012; 16(1): 48. CrossRef
A Case of Anal Malignant Lymphoma
Satoru Umegae, Koichi Matsumoto, Tatsushi Kitagawa, Midori Noji, Takayuki Yamamoto, Masaaki Ishii, Kiyoshi Narita, Takahiro Torii, Tomonori Himan, Manabu Yamazaki
Nippon Daicho Komonbyo Gakkai Zasshi.2011; 64(5): 332. CrossRef
Plasmablastic lymphoma associated to Crohn's disease and hepatitis C virus chronic infection
Rocio Plaza, Angel Ponferrada, Dulce M. Benito, Noelia Arevalo, Maria Angeles Foncillas, Maria Luisa de Fuenmayor, Mercedes Aldeguer
Journal of Crohn's and Colitis.2011; 5(6): 628. CrossRef
Plasmablastic lymphoma in the ano-rectal junction presenting in an immunocompetent man: a case report
Mayur Brahmania, Thomas Sylwesterowic, Heather Leitch
Journal of Medical Case Reports.2011;[Epub] CrossRef
Oral cavity and extra-oral plasmablastic lymphomas in AIDS patients: report of five cases and review of the literature
M Corti, M F Villafañe, A Bistmans, A Campitelli, M Narbaitz, P Baré
International Journal of STD & AIDS.2011; 22(12): 759. CrossRef
Assessment of Plasmablastic Lymphoma by F-18 FDG PET/CT
Thomas Cazaentre, Laurence Sanhes, Guillaume Laurent, Keltoum Costa, Xavier Vallantin, Dominique Pascal-Ortiz
Clinical Nuclear Medicine.2010; 35(11): 882. CrossRef

10,799 View
58 Download
17 Crossref

Original Articles

A Phase 2 Study with Vinorelbine and Ifosfamide in the Inoperable Non - small Cell Lung Cancer: Moon Hee Lee, Young Jin Yoo, Soo Mi Bang, Gyung Hae Joung, Hyo Jin Kim, Dong Bok Shin, Soon Nam Lee, Seong Rok Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 1999;31(5):972-978.

Abstract PDF: PURPOSE
A phase II study of vinorelbine and ifosfamide combination chemotherapy in patients with advanced or recurrent non-small cell lung cancer (NSCLC) was conducted to assess response rate, response duration, and toxicites.
MATERIALS AND METHODS
Patients with advanced NSCLC who had no prior systemic chemotherapy were eligible. They have no central nervous system metastasis and recurrent or progressive disease after surgery or radiotherapy. Each cycle consisted of vinorelbine 25 mg/m' i.v. days 1 & 8, and ifosfamide 2 g/m i.v. days 1, 2 & 3 with Mesna and treatments were repeated every 21 days.
RESULTS
Forty patients with advanced or recurrent NSCLC were treated at multi center between March, 1997 and March, 1998. Six patients were not evaluable because five patients refused therapy after the first course and one patient was protocol violation. Of 34 evaluable patients, objective responses were seen in 11 (32.4%) patients (CR 0%, PR 32.4%). The median duration of response was 16.4 weeks. The median overall survival was 9.5 months. The toicities of this regimen were acceptable without treatment related toxic death.
CONCLUSION
We concluded that combination regimen of vinorelbine and ifosfamide was effective and tolerable in the treatment of advanced non-small cell lung cancer.

2,543 View
16 Download

A Phase 2 Study of VP-16 , Ifosfamide , and Cisplatin ( VIP ) Combination Chemotherapy Plus Concurrent Thoracic Irradiation for Limited Small Cell Lung Cancer: Seok Ah Im, Moon Hee Lee, Chul Won Jung, Dae Seog Heo, Yung Jue Bang, Young Soo Shim, Chan Il Park, Noe Kyeong Kim; J Korean Cancer Assoc. 1999;31(2):306-312.

Abstract PDF: PURPOSE
A phase II study of etoposide, ifosfamide, cisplatin combination chemotherapy and concurrent thoracic irradiation in patients with untreated limited small cell lung cancer (SCLC) was conducted to assess toxicities, response rate, response duration, and median survival.
MATERIALS AND METHODS
Patients with histologically confirmed SCLC with a ECOG criteria 2 and adequate renal function and bone marrow reserve were eligible. Each cycle consisted of VP-16 100 mg/m i.v, days 1-3, ifosfamide 1,200 mg/m i.v. days 1-3 with Mesna, and cisplatin 30 mg/m i.v. days 1-3. Cycles were repeated every 21 days. Concutrent thoracic itradiation was given as total 40-45 Gy for 4-5 weeks beginning within 24 hours of the third cycle. Patients with complete remission received prophylactic cranial irradiation after the 6th cycle.
RESULT
Forty two patients with limited SCLC were treated at Seoul National University Hospital between December 1993 and August 1996. Three patients were not evaluable because of lost to follow up (2 patients) and one treatment-related early death. Of 39 evaluable patients, responses were seen in 38 (97%) patients including 22 (56%) complete responses and 16 (41%) partial responses. The median remission duration was 65 wks. The median disease free survival was 60 wks. The median overall survival was not reached and 2-year survival was 69% with median duration of follow up of 63.5 wks. Hematologic side effects (WHO Gr>III/IV) of evaluable 228 cycles of chemotherapy were leukopenia in 34%, thrombocytopenia in 16%. One patient expired after prolonged leukopenia and sepsis. Nonhematologic side effects (WHO Gr>II) included nausea and vomiting (17%) and peripheral neuropathy (2%).
CONCLUSION
VIP combination chemotherapy with concurrent thoracic irradiation is effective and tolerable in limited SCLC.

2,553 View
13 Download

Phase 2 Trial of FLP ( 5-FU , Leucovorin , Cisplatin ) Combination Chemotherapy for Advanced Gastric Cancer: Young Iee Park, Moon Hee Lee, Sung Woo Han, Woo Jung Park, Dong Gyu Kim, Jin Lee, Jin Seok Ahn, Jung Ae Rhee, In Sook Woo, Young Suk Park; J Korean Cancer Assoc. 1998;30(1):55-62.

Abstract PDF: PURPOSE
Advanced gastric cancer, the most common malignancy in Korea is a kind of systemic disease. At dignosis, 50~80% of patients have systemic cancer. Therefore, the most patients require systemic chemotherapy. Cisplatin and 5-FU have been suggested to be active in the treatment of gastric cancer, a high response rate was observered with a combination of 5-FU infusion and cisplatin, and the biochemical modulation of 5-FU by leucovorin has been demonstrated to enhance the activity of 5-FU in gastrointestinal tract cancer.
MATERIALS AND METHODS
The patients with advanced gastric cancer whose disease had relapsed or unresectable were treated with 5-FU(800 mg/m2 12 hr IV infusion, D 1~5), leucovorin(20 mg/m2 IV, D 1~5, max. 30 mg), cisplatin(100 mg/m2 15min IV dripping, D1). The cycles of treatment were repeated at 3-weeks intervals.
RESULTS
Between Sep. 1994 and Aug. 1996, previously untreated 44 patients(39 eligible patients) were admitted to this study, the median age was 55 years(range 17~73) and male to female ratio was 20:19. The rate of complete remission was 5%(2/39), the rate of partial remission was 21%(8/39). The median-response duration was 26 weeks(5+~38+ ). The median-time to progression was 25 weeks(4+~62+). The range of overall survival time was from 4 to 62+ weeks. 24 weeks survival rate was 71.5% but the median survival time was not reached. The leukopenia and anemia were the main hematologic toxicities. Non-hematologic side effects were nausea, vomiting, diarrhea, stomatitis, peripheral neuropathy. These toxicities were observed commnonly, but tolerable. Two treatment-related deaths were associated with sepsis.
CONCLUSION
Based on these results, FLP combination chemotherapy seems to be a moderate efficacy for advanced gastric cancer with tolerable toxicities. To confirm the efficacy further, the long-term follow up and a large scale of clinical studies are needed.

2,995 View
14 Download

First
Prev
Page of 1
Next
Last

Search